• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Elscint numbers jump on CT sales growth

Article

The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same

The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same perioda year ago.

The company's net income was up as well, to $4.9 million inthe most recent quarter, compared to $2.7 million in the secondquarter of 1995. Net income for the second quarter of 1995 includes$1.6 million from settlement of a patent dispute with Sopha Medical(SCAN 7/28/93).

Dr. Thomas Spackman, president of Elscint's U.S. subsidiary,said the numbers were paced by strong growth in internationalmarkets, as well as a good performance in CT both in the U.S.and globally.

"There has been a real resurgence in some of the markets,in Eastern and Western Europe, and to some extent North and SouthAmerica," Spackman said. "There is growth in rest ofthe world, and the U.S. is hanging on."

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.